Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ramucirumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated as injection solution, concentrate solution for intravenous route o administration. Cyramza as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy, in combination with FOLFIRI (irinotecan, folinic acid, and 5 -fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been previously treated with sorafenib. Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.
The drug candidate is under development for the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT), hepatocellular carcinoma, malignant mesothelioma, pancreatic adenocarcinoma, adenocarcinoma of the gastroesophageal junction, bladder cancer, urethral cancer, non-small cell lung carcinoma, squamous non-small cell lung cancer, metastatic colorectal cancer, progressive carcinoid tumors, squamous cell carcinoma of the esophagus, pancreatic neuroendocrine tumor, gallbladder cancer, small-cell lung cancer and metastatic biliary tract cancer, metastatic thymic carcinoma, gastroesophageal junction region (GEJ) cancer, pediatric solid tumors including CNS, non-CNS tumors. The drug candidate was also under development for the treatment of refractory/relapsed synovial sarcoma, HER2 negative metastatic breast cancer and gastric cancer as first-line therapy, fallopian tube cancer, peritoneal tumor, epithelial ovarian cancer, metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, metastatic melanoma, bladder cancer, metastatic transitional cell cancer (urothelial cell cancer) including bladder cancer, urethral cancer, ureter cancer, recurrent glioblastoma multiforme (GBM), mantle cell lymphoma, HER2 positive metastatic breast cancer as second-line therapy, metastatic renal cell carcinoma, signet ring cell squamous cell carcinoma. It is administered through subcutaneous route.
For a complete picture of Ramucirumab’s drug-specific PTSR and LoA scores, buy the report here.